Evaluation of uveoretinitis associated with Behcet's disease after discontinuation of successful infliximab therapy

Evaluation of uveoretinitis associated with Behcet's disease after discontinuation of successful infliximab therapy - Evaluation of uveoretinitis associated with Behcet's disease after discontinuation of successful infliximab therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025670

Enrollment

Registered

2017-01-16

Start date

2014-10-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveoretinitis associated with Behcet&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with low activity of ocular inflammation for at least 2 years before infliximab discontinuation 2)Patients with low levels of retinal vascular leakage before infliximab discontinuation 3)Patients with low activity of systemic symptoms

Exclusion criteria

Exclusion criteria: 1)Patients with shortening of the interval between infliximab infusions 2)Patients with poor visual acuity during remission 3)Patients with neuro-Behcet's disease, intestinal Behcet's disease, vascular Behcet's disease

Design outcomes

Primary

Measure	Time frame
Evaluation of frequency of ocular attacks	—

Secondary

Measure	Time frame
Evaluation of visual acuity, fluorescein angiography, extraocular symptoms	—

Countries

Japan

Contacts

Public ContactHiroshi Keino

Kyorin University School of Medicine Ophthalmology

keino@eye-center.org0422-47-5511

Outcome results